$
0. 23
+0.02
+9.5238%
$
273.95M Market Cap
- P/E Ratio
- Div Yield
3.96M Volume
- Eps
$ 0.21
Previous Close Want to track CYDY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
CytoDyn OTCMKTS: CYDY Chief Financial Officer Robert E. Hoffman outlined the company's clinical-development plans for leronlimab, a CCR5-targeting humanized monoclonal antibody being studied in metastatic colorectal cancer, triple-negative breast cancer and other solid tumors.
Marketbeat | 4 weeks ago
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
Seekingalpha | 5 months ago
2026 © Marketlog. All Rights Reserved.
